HT-VA outperformed Danish drug Novo Nordisk’s blockbuster semaglutide drug in key gene expression markers tied to liver fat regulation, the company said. ・The company is now looking to advance the ...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced positive data from its HT-VA study, conducted under its Cooperative Research and Development ...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, today announced that the China National ...

In the open-label PK cohort, 100% of evaluable patients achieved clinical response by Week 6, accompanied by an approximate 50% reduction in investigator-assessed disease severity (using the ARIGA ...

Detailed price information for Hoth Therapeutics Inc (HOTH-Q) from The Globe and Mail including charting and trades.

NEW YORK, April 12, 2021 /PRNewswire/ — Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, together with its manufacturing partner, has successfully completed ...

Over 65% of Patients Reported Reduced Pain and Itching; Zero Disruptions to EGFR Cancer Therapy with ~99% Lower Systemic Exposure NEW YORK, April 1, 2026 /PRNewswire/ ...